Skip to main content
Equibles
CMMB logo

CMMB · Chemomab Therapeutics Ltd.

Track CMMB — free

Use CMMB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.70 -0.13 (-4.59%) At close · Sep 4
Rebalance outlook locked
Market Cap
$20.00M
Shares
7.33M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.83 Open$2.82 Day$2.71–2.94 52W close$1.36–3.50 Avg vol 30d93K Short int113K · 1.5% float · 1.9d Short vol13% Last earningsMay 11, 2023 DataAug 2025–Sep 2026 Filing10-Q · May 11

Raw chart and full-history price indicators begin at the captured split on Aug 26, 2025; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed May 11, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-6.3%
Trailing year
Short interest
1.5%
Latest settlement · 1.9 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.47
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +54%
above
Price vs 50-day avg +48%
above
RSI (14) 85
overbought
MACD trend Positive
52-week position 69%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +57%
trailing
6-month return +55%
trailing
YTD return +72%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-13% holders QoQ · +1 funds added
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
1.54% of float · ▼ -27.3% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Poor
EPS growth −54%
Y/Y
Free cash flow $-11.1M
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −61%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+54% Bullish
Price vs 50-day avg
+48% Bullish
RSI (14)
85 Bearish
MACD trend
Positive Bullish
52-week position
69% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-13% holders QoQ · +1 funds added
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
1.54% of float · ▼ -27.3% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $3 · 69% Range high $4
vs 200-day avg +54% vs 50-day avg +48% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CMMB
Chemomab Therapeutics Ltd.
this stock
$20.00M +71.5% — — 1.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +23.1% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +9.3% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
13
% held
5.2%
Net QoQ
+28.3K sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
113.2K
Days to cover
1.9d
Change
-42.4K sh
View
Short Volume
Short vol %
13%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
3.5K
Value
$6.6K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
49.2%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$6.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-9.0M
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 19, 2026
This year
9
View
Proposed Sales
Value
$1.0M
Shares
500.0K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$10.0M
Filed
Aug 9, 2024
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 11, 2026
Last call
May 11, 2023
View
Investor Relations
Upcoming events
1
View

Performance

Raw-price comparisons begin at the captured split on Aug 26, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
CMMB +4.0% +57.2% +54.6% +4.0% +71.5%
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY +3.8% +56.6% +37.9% +3.2% +58.1%
Key facts CIK 1534248 CUSIP 16385C203 13F (30d) 9 filings 9 filers Visit website Investor relations